RxDoctor Payments Data

Aaron Wood, MD

Family Medicine · New Braunfels, TXNPI 1558713339

Payments from drug & device makers

$1,787in general payments, 2019–2025

Across 22 payments — averaging $81.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$249
  • Lilly USA, LLC$238
  • Si-bone, Inc.$229
  • Medtronic$195
  • Abbott$150
  • AstraZeneca$135
  • plus $591 from 9 others

What the payments were for

  • Food & beverage$1,787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,787 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$145,459
Medicare patients
405
Services billed
1,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$138,784
OzempicSemaglutide70$112,803
MounjaroTirzepatide56$74,297
TrulicityDulaglutide46$58,170
JanuviaSitagliptin Phosphate33$51,180
EliquisApixaban33$44,487
FarxigaDapagliflozin Propanediol12$18,265
MyrbetriqMirabegron13$16,498
Tresiba Flextouch U-200Insulin Degludec14$16,092
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$5,361
Atorvastatin Calcium397$3,257
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,178
Levothyroxine Sodium311$3,116
Tamsulosin Hcl116$2,712
Rosuvastatin Calcium231$2,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$238$132,467102 claims
Novo NordiskOzempic$78$112,80370 claims
MerckJanuvia$42$51,18033 claims
AstraZenecaFarxiga$135$18,26512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →